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Abstract
Background: A high percentage of cervical cancer cases have not undergone cytological tests within 10 years
prior to diagnosis. Different population interventions could improve coverage in the public system, although costs
will also increase. The aim of this study was to compare the effectiveness and the costs of three types of
population interventions to increase the number of female participants in the screening programmes for cancer of
the cervix carried out by Primary Care in four basic health care areas.
Methods/Design: A cost-effectiveness analysis will be performed from the perspective of public health system
including women from 30 to 70 years of age (n = 20,994) with incorrect screening criteria from four basic health
care areas in the Valles Occidental, Barcelona, Spain. The patients will be randomly distributed into the control
group and the three intervention groups (IG1: invitation letter to participate in the screening; IG2: invitation letter
and informative leaflet; IG3: invitation letter, informative leaflet and a phone call reminder) and followed for three
years. Clinical effectiveness will be measured by the number of HPV, epithelial lesions and cancer of cervix cases
detected. The number of deaths avoided will be secondary measures of effectiveness. The temporal horizon of the
analysis will be the life expectancy of the female population in the study. Costs and effectiveness will be
discounted at 3%. In addition, univariate and multivariate sensitivity analysis will be carried out.
Discussion: IG3 is expected to be more cost-effective intervention than IG1 and IG2, with greater detection of HPV
infections, epithelial lesions and cancer than other strategies, albeit at a greater cost.
Trial Registration: Clinical Trials.gov Identifier NCT01373723
Background
Cancer of the cervix is the second most frequent cancer
in the world among women, with at least 400,000 new
cases being detected every year [1]. Despite being one of
the neoplasms with an easy preventive and therapeutic
approach, it remains an important cause of morbid-
mortality, although the figures in developed countries
are lower than those in developing countries. In Spain,
the incidence of cervical cancer is 7.1%, with a mortality
of 3.1 cases per 100,000 women/year and showing a
progressive trend [2]. In the Department of Pathologic
A n a t o m yo fo u rr e f e r e n c eh o s p i t a lC .H .P a r cT a u l í ,1 8
cases of invasive cervical cancer and 464 pre-malignant
lesions (ASCUS, AGUS, LSIL, HSIL) have been diag-
nosed corresponding to women referred to our sexual
and reproductive primary health care services (SRHC)
from 2003 to 2008.
The aetiological cause of cervical cancer is infection by
the human papilloma virus (HPV) [3]. Seroptypes 16
and 18 are the most prevalent types in our setting and,
together with serotypes 45, 31, 33, 52, 58 and 35, are
responsible for 90% of cervical cancer, with a global pre-
valence of 99.7% of cases[4,5]. The systematic vaccina-
tion of 12-year-old girls initiated in 2008 may have an
important impact on the prevalence of HPV within 15
to 20 years, with a potential reduction of 67 to 71% of
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any medium, provided the original work is properly cited.this virus [6]. High and continuous coverage of this vac-
cine in girls from 11 to 14 years of age may lead to a
redefinition of screening, a variation in the schedules
and, perhaps, the incorporation of primary screening
with the HPV detection test in vaccinated women [7].
The Papanicolau cytology test introduced in the 1960s
has allowed a reduction of up to 80% in the mortality
by this disease with early diagnosis of precancerous
lesions [8]. Thus, this continues to be the main diagnos-
tic test used in screening programmes worldwide. One
of the characteristics of the cytology test is its low sensi-
tivity requiring periodical repetition. The test for the
determination of HPV has recently been included in the
screening programmes and, since 2006, 213 HPV posi-
tive cases have been detected in the study area.
In Catalonia, the protocol, which was revised and
modified by the Oncology Management Director Plan
and the Catalan Institute of Oncology in 2006, did
incorporat the establishment of triennial periodicity of
cytologies in women from 25 to 65 years of age as well
as the incorporation of the HPV test in women from 40
to 65 years of age with no prior cytology within the pre-
vious 5 years or with a cytology carried out for longer
than 5 years, abnormal cytology (no specified atypical
squamous lesions) and women with post-conization
control of intraepithelial lesions. The protocol also
emphasizes the preventive role of the Basic Health Care
Area (BHCA) and incorporates the figure of the midwife
as a skilled professional for sample obtainment [9].
The research team decided to establish the age range
for the population study between 30 to 70 years. The jus-
tification for the lower age limit is based on: 1.- although
the second decade of life is when the greatest peak of
infection by HPV is produced, the probability of its per-
sistence is lower in young women, since the infection dis-
appears in 90% of the cases after two years of follow up
[7,10] 2.- early actions increase unnecessary interven-
tions, generating anxiety in the woman and a work and
economic overload on the public health care system [11].
3.- establishing a limit after 30 years of age will detect the
lesions derived from the persistence of HPV which, with
treatment, will preserve fertility and avoid the evolution
of the lesion towards invasive cancer [12].
In addition, the justification of the upper age limit is
based on: 1.- recommendations of the Spanish Consen-
sus for secondary prevention of cancer of the cervix in
2006 [13]. 2.- resolution num. 287 of the European
Council (June 10, 2008 Luxemburg), related to the
volume of cancer cases in the European Union and the
mechanisms to reduce them [14]. 3.- an increase
observed in the incidence of cancer in women born in
the decade from 1930 to 1940 [2,13,14].
Eighty percent of the cases of cervical cancer in Cata-
lonia have not undergone previous cytology during the
10 years prior to diagnosis [15]. Thus, an increase in
screening coverage should be a priority objective for
health care authorities if cervical cancer cases are to be
reduced and women who do not periodically undergo
cytology are to be identified. Some authors have
reported that factors such as ethnic origin, age, educa-
tion, and the socioeconomic levels condition participa-
tion in screening programmes [16]. Reasons to justify
why women do not attend screening could include: (a)
the perception of vulnerability; (b) the benefits perceived
of screening; (c) anxiety; (d) bothersome; (e) fear of can-
cer; ans, (f) familial difficulties or personal circum-
stances [16,17]. With regard to the factors related to the
health care system which influence the participation in
screening in our setting, some authors have suggested:
the absence of populational programmes, low sensitiza-
tion with respect to preventive attitudes in cohorts of
women of advanced age and the therapeutic health care
overload in the primary care centres (PCC) [15].
The opportunistic preventive screening program in the
Catalonian public health care system is carried out by the
Sexual and Reproductive Health Care (SRHC) service
located in the PCC and BHCA.T h ec o v e r a g eo fw o m e n
attending our health care system (CIH) in 2008 (41.6%,
figure obtained from the Systems of Primary Health Care
Information (SPHCI) of the study setting) was similar to
the one remaining at the SRHC of Catalonia.
A systematic review of the Cochrane collaboration
[16], which evaluates interventions to stimulate the par-
ticipation of women in the screening of this disease,
concluded that invitations and educational interventions
seem to be the most effective methods to increase abso-
lute participation in the screening, although, to date,
this has not been analysed from the point of view of
efficiency.
At present, no study has evaluated from the efficiency
point of view these interventions, though economic eva-
luation has been highly recommended for the cervical
cancer screening programmes and HPV infections
[18-20]. One key question influencing participation in
screening programmes has been precision of population
registers if an invitation letter is used (i.e. in some stu-
dies from 20 to 30% of the invited women were lost due
to incorrect contact information) [21].
Due to the high prevalence of cervical cancer cases in
this particular county we propose to launch a compari-
son of three different alternatives to improve the present
coverage of the populational screening programmes in
all the BHCA, therefore facilitating accessibility of popu-
lation to the public health care system. The screening
model proposed is centred on the recruitment of
women with incorrect screening, performing cytology
and the hybrid capture test for HPV to add diagnostic
resolution due to the greater sensitivity of the test and
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Hence, systematic screening should be incorporated
since these women have a greater risk of having cervical
disease because of not having visited the health care sys-
tem before. Therefore, this would facilitate earlier action
in detecting pre-malignant lesions, helpingto t reduce
the incidence of invasive cancer. To achieve so, the
research team propose three different interventions,
consisting in sending: (a) an invitation letter to partici-
pate in the screening; (b) an invitation letter and an
informative leaflet; and, (c) an invitation letter, an infor-
mative leaflet and a phone call reminder. Therefore,
there is: one common action in the three different inter-
ventions, which has been scientifically validated as effec-
tive, consisting in a personalized invitation letter sent by
the primary health care professionals including a fixed
appointment to undergo through a cytology test and,
other two different interventions (informative leaflet and
reminder call) to evaluate approaches for which there
are few studies assessing the effectiveness of attendance
to screening programmes. Following the indications of
the National Health Care System to optimise the
interventions of cancer prevention [18], the aim is to
assess which is the most cost-effective intervention for a
cervical cancer screening programme.
Method/Design
An economic evaluation of three populational screening
strategies for cervical cancer will be performed. (Figure
1, 2) Particularly, a cost-effectiveness analysis will be
conducted. These interventions will be compared to the
current opportunistic screening strategy using data of
the multicentre randomised trial (CRICERVA). The ana-
lysis will be conducted from the National Health Care
System perspective [22].
Design
Pragmatic, blinded, multicentre, randomised, controlled
clinical trial with four branches, and a three years fol-
low-up. The randomisation unit was BHCA.
Setting
Primary Health Care Services (PCS) of Cerdanyola-
Ripollet, province of Barcelona, comprising 4
Study year     First year  Second year  Third year 
Study month     1  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  26  27  28  29  30  31  32  33  34  35  36 
Tasks  D o n e                                       
Diffusion of the project  X                                                                                        
Definitive protocol 
elaboration   X                                                                                       
Consultation to reference 
/    X                                                                                       
Obtaining  of the list of 
women who meet the 
criteria that define the study 
population  X                                                                           
           
Presentation CEIC  X                                                                                      
Pilot study   X                                                                                      
Randomization of 
interventions   X                                                                                     
Evaluation of the pilot test 
and timely changes       X                                                                                      
Development of the 
materials for the 
development of the study 
and training of professionals       X                                                                          
           
Training of health 
professionals in the 
management of the 
ƚĞůĞŵĂƚŝĐnotebook  for data 
collection       X                                                                           
           
Implementation of 
sequential character of three 
interventions                                                                              
            
Inclusion of women in the 
screening. Collection of data 
in  QRD                      
         
New telephone notice to the 
women who did not attend 
the established appointment                                                                            
              
Closure of data 
collection.Quality control of 
registries                                                                              
               
Statistical analysis                                                                                              
Preparation and diffusion of 
results                                                                                                
Preparation of the final 
report                                                                                          
CEIC: Clinical Research Ethical Committees; QRD: Online workbook data collection
Figure 1 Timing of the Project.
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Page 3 of 7municipalities and 5 BHCA. The population covered by
this PCS is 120,293 inhabitants over 14 years. As there
are four study groups and 5 BHCAs, only 4 BHCAs
with most homogeneous socioeconomic criteria will be
considered.
Population
20,994 women from 30 to 70 years of age with incorrect
screening criteria (data obtained from SPHCI) ascribed
to the BHCA will be included in the study. Incorrect
screening will be defined as [9]: 1.- No cytology in the
last 3 years from women between 30 to 40 years, 2.- No
cytology in the previous 5 years from women between
40 to 65 years, 3.- No previous cytology history for
females older than 65 years or women who have not
had their last cytology before the age of 60. The exclu-
sion criteria will be: (a) hysterectomised women, with a
current history of pre-malignant lesions (AGUS,
DIFFUSION 
OF PROJECT
S SELECTION OF 
PARTICIPANTS
INCLUSION AND 
EXCLUSION CRITERIA
Randomization by
Municipalities (cluster)
Pilot trial
GNI
Non – intervention group
Opportunistic Cytology
GI1
Intervention Goup 1
Invitation letter
GI2
Intervention Group 2
Invitation letter +
information leaflet
GI3
Intervention Group 3
Invitation letter +
information leaflet +
telephone reminder
Cytology of  private health
Exclusion + CDRe Exclusion + CDRe Exclusion + CDRe
Cytology of  private health Cytology of  private health
Cytology  performed
No reply 
Cytology  performed Cytology  performed
No reply  No reply 
Phone call at 10 days
No reply Citology Cytology of  private health
CRDe
Phone call
CDRe
Exclusion + CDRe
Figure 2 Study Algorithm.
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Page 4 of 7ASCUS, LSIL, HSIL), carcinoma in situ and cervical-
uterine cancer, HIV positive or other causes of immuno-
suppression (since these women follow a specific proto-
col); (b) those residing outside the study setting for
more than 6 months; and (c) those ascribed to the study
BHCA but with a physician assigned in an UBA of
another zone different from the one considered in the
study.
Sample size
The sample size has been calculated based on the detec-
tion of a difference in effectiveness compared with the
non intervention group (NIG). It has been calculated by
multiplying the size of a simple randomised design by
the design effect or factor of inflation. For the simple
randomised design, on accepting an alpha risk of 0.05
and a beta risk of 0.20 in a bilateral contrast, 59 subjects
will be required in the first group and 59 in the second
group to detect a difference greater than or equal to
28.4% in the screening coverage of the 41.6% in the
NIG. The lost to follow up rate has been estimated at
20%. The calculation of the sample has been performed
with the Granmo 5.2 computer programme for Win-
dows. According to a review of the literature [23-25],
considering an intraclass correlation coefficient of 0.05
and a mean number of 3,500 women from 30 to 70
years of age with incorrect screening by BHCA, the
design effect will be 176 and thus, 20,768 women with
incorrect screening will be required.
Outcomes measures and statistical analysis
- Decision analysis
A Markov model will be developed to simulate the nat-
ural history of cervical-uterine cancer and to measure
the impact, on costs and outcomes, of three different
screening strategies. This same model of analytical deci-
sion has been used in several screening studies for cervi-
cal cancer [26-34]. The parameters of this model,
clinical variables and costs, which would be included,
are shown in the following sections of this protocol
[35,36]. The population will be distributed across differ-
ent health states of the model using transition probabil-
ities over time. The temporal cycles of the Markov
model will be 6 months of length during which time the
state of health of the women may change or remain the
same. These probabilities are conditioned to age, state
of the HPV and history of the disease. The 11 states of
health considered will be: healthy women, HPV infec-
tion, low grade intraepithelial lesion (L-SIL), high grade
epithelial lesion (H-SIL), FIGO EIa stage invasive cancer
(FIGOEla), FIGO EIb stage invasive cancer (FIGEIb),
FIGO EIIa stage invasive cancer (FIGOEIIa), FIGO
ELLb stage invasive cancer (FIGOEIIb), FIGO EIII stage
invasive cancer (FIGOEIII), FIGO EIV stage invasive
cancer (FIGOEIV), and death. These health states,
recommended by the clinical experts of this study, are
consistent with those extensively reported in the eco-
nomic literature [26-34].
- Clinical effectiveness measures
The main effectiveness measures of this evaluation
would be the total number of cytologies performed,
HPV infections detected, lesions of different grades
detected, episodes of cancer detected and the number of
deaths avoided. The efficacy of the interventions will be
obtained from the CRICERVA clinical trial.
- Costs measures
Micro-costing techniques will be used to estimate the
health care costs of the different screening intervention
of cervical cancer and treatments of different health
states [37]. The costs will be presented in 2013 Euros
(€) (year foreseen to finalize the study). Primary data of
CRICERVA clinical trial will be used whenever possible.
The costs will include the costs of: diagnosis, interven-
tions and treatment for all women. The costs of diagno-
sis will include the cost of cytology, the HPV
determination test and the control visit by the midwife
or gynaecologist. The cost of the interventions will
cover the cost of a full-time administrator, the persona-
lized screening invitation letters, the informative leaflets
and phone calls. The cost of treatment will depend on
the state of health of the women but may include the
costs of the visits to the gynaecologist, cytology tests,
HPV determination, control visits with the physician,
costs of radical hysterectomy, radiotherapy, chemother-
apy, etc.
- Temporal horizon
The temporal horizon of the analysis will be the lifetime
period of the woman.
- Discount rate
The discount rate to calculate costs and clinical out-
comes will be 3% [22].
- Cost-effectiveness analysis
The cost-effectiveness analysis will be conducted com-
paring costs and effectiveness, measured in natural
units, of the different alternatives to usual practice. In
most cases the data will be obtained from the CRI-
CERVA clinical study. The comparison will be per-
formed using the Incremental Cost-Effectiveness Ratio
(ICER) defined as the ratio of the difference in costs and
the difference in effectiveness. The results will be
expressed in terms of €/per unit of effectiveness.
- Uncertainty
To study the uncertainty, an univariate and multivariate
deterministic sensitivity analysis will be undertaken of
the relevant parameters considered.
- Statistical analysis
All the statistical analyses will be performed using the
SPSS v.18 programme and Microsoft Excel. The
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principle to be determined. Descriptive analysis of each
of the groups will be performed. The mean values and
standard deviations of the costs and the corresponding
intervals of confidence at 95% will be presented. The
final result will be reported in terms of effectiveness,
cost and ICERs for each of the alternatives compared.
Ethical Aspects
The investigators are committed to respect the prevail-
ing norms of Good Clinical Practice as well as the
requisites of the Declaration of Helsinki and the clauses
of general and particular ethical conditions related to
the right to privacy, anonymity and confidentiality.
Neither the first name nor surname or any other type of
data indicating the identification of the women will be
registered. Therefore, identification will be made by
numeric codes. Since this type of study is developed in
the usual clinical setting, authorisation and support
must be and has already been granted by the representa-
tives and authorities of the collectives involved and thus,
individualised informed consent is not necessary. None-
theless, the research team decided that women attending
the consultation for the cytology should sign the con-
sent form. The protocol has been evaluated by the ECCI
of the Jordi Gol IIPC.
Limitations
Randomisation by groups will avoid the potential intro-
duction of selection bias which may be produced among
the interventions performed at the same site. Since the
characteristics of the study do not allow the application
of the double-blind masking technique, the masked
response evaluation will be used to ensure that the mea-
surement and interpretation of the dependent variables
is carried out the same way in all groups. The possible
loss of information, which may be produced in women
d o i n gs c r e e n i n go u t s i d ep u b l i ch e a l t hc a r ei ft h e ya r e
not contacted by the research team, will be minimised
with a phone call reminder. This will be made when the
women do not attend the appointment. The language
difficulties in women from other countries will be solved
with cultural mediators at each site. Within the setting
of the study, the administrative personnel have been
updating the postal addresses of the users attending the
BHCA since 2007 and, therefore the postal registry is
quite precise, thereby reducing the potential loss of
letters.
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